'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate.
During a phase III open study of depot leuprolide for stage D2 cancer of the prostate, we studied the effect of depot leuprolide on chronic leuprolide users. To determine whether there was a transient elevation of testosterone or luteinizing hormone (LH) 4-24 h and 3-5 days following the monthly injections, we monitored the changes of testosterone and LH before injection and 24 h post-injection in 10 patients who have been under depot leuprolide Rx for 24-36 weeks, and in 35 patients before injection and 3-5 days post-injection who have received depot leuprolide for 8-24 weeks prior to monitoring. Comparison of the data between pre-injection within 24 h and 3-5 days post-injection showed no significant changes of testosterone and LH values between these levels for either testosterone (P = 0.31) or LH (P = 0.45). We therefore conclude that there was no 'acute on chronic' effect of depot formulation in chronic users of depot leuprolide.
Sharifi
R
R
Department of Surgery, College of Medicine, University of Illinois, Chicago 60612.
Soloway
M
M
Clayton
M
M
Mounzer
A
A
Strub
M
M
Siami
P
P
Lee
M
M
D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage*; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013739:Testosterone / Q000378:metabolism
D003692:Delayed-Action Preparations; D013739:Testosterone; D007986:Luteinizing Hormone; D016729:Leuprolide